references
TRANSLATION
New CL combination therapies
LEISHMANIASIS
Objective: Further explore opportunities to better use the existing approved treatment approaches for CL when used in combination. Main partners: Programa de Estudio y Control de
Parasitarias y Enfermedad de Chagas; BOLIVIA: Collective of Applied Studies and Social Development; Universidad Autónoma Juan Misael Saracho; Universidad Mayor de San Simon; SPAIN: ISGlobal, Centre de Recerca en Salut Internacional de Barcelona; Hospital General de Valencia; SPAIN/BOLIVIA: Platform of Integral Care for Patients with Chagas Disease; JAPAN: Eisai Co. Ltd
Emodepside
FILARIAL DISEASES
Objective: Develop emodepside as a new macrofilaricidal treatment for patients suffering from onchocerciasis. Main partners: Bayer HealthCare, Germany
Enfermedades Tropicales, Universidad de Antioquia, Medellin, Colombia; Universidad Peruana Cayetano Heredia, Lima, Peru
Fexinidazole
CHAGAS DISEASE
New benznidazole regimens +/- fosravuconazole
CHAGAS DISEASE
Objective: Evaluate fexinidazole for treatment of chronic indeterminate Chagas disease. Main partners: ARGENTINA: Instituto de Investigaciones en
Two ‘4-in-1’ LPV/r FDC granules
PAEDIATRIC HIV
Objective: Evaluate new therapeutic regimens of benznidazole, in monotherapy and in combination with fosravuconazole, for the treatment of adult patients with chronic indeterminate Chagas disease. Main partners: ARGENTINA: Fundación Mundo Sano and
Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres” - INGEBI-CONICET; BOLIVIA: Collective of Applied Studies and Social Development; Platform of Integral Care for Patients with Chagas Disease, Tarija and Cochabamba; Universidad Autónoma Juan Misael Saracho; Universidad Mayor de San Simon; SPAIN: ISGlobal, Centre de Recerca en Salut Internacional de Barcelona
Objective: Develop and register two solid taste-masked first-line LPV/r-based fixed-dose formulations with two NRTIs, 3TC plus ABC or AZT. Main partners: Cipla, India; Department of Health, South
Africa; Medical Research Council, UK; UNITAID; Centre for Disease Control and Prevention (CDC)/President’s Emergency Plan for AIDS Relief, USA; Médecins Sans Frontières; Necker Institute, France; various academic partners in South Africa and Kenya; AbbVie, USA; WuXi AppTech, China
ELEA; Administración Nacional de Laboratorios e Institutos de Salud; Instituto Nacional de Epidemiología Dr Fatala Cháben; Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres” - INGEBI-CONICET; Centro de Chagas y Patologia Regional, Hospital Independencia, Santiago del Estero; Fundación Para el Estudio de las Infecciones
AbbV4083 (TylAMac)
FILARIAL DISEASES
Objective: Develop TylAMac as an anti-Wolbachia therapy and assess its macrofilaricidal efficacy. Main partners: AbbVie, USA; AWOL, UK
• R&D Portfolio
11